Bristol Myers Squibb

The innovation centre in Hyderabad will support a global approach to patient treatment rather than India-focused treatment and be part of the global ecosystem, the executive vice president of the company underlined.

Syngene: Multi-year contract with Zoetis adds to long-term visibility

The risk to watch is the execution in the field biologics and the pending regulatory approvals

Ideas for profit | Dr Reddy’s: COVID opportunity key growth lever

Dr Reddy’s strong product pipeline is suitably supported by R&D & capex budget. In FY22, product launch momentum is expected to remain strong. Another emerging growth lever for DRL are China, India & Europe opportunities. Given emerging earnings catalysts, Dr Reddy’s remains an accumulation opportunity on declines.

Dr Reddy’s: COVID opportunity gets wings

Along with Sputnik V and 2-DG, Dr Reddys has further strengthened its COVID opportunity, which makes it a worthy watch

Drugmaker Bristol-Myers to buy Celgene for $74 billion

Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene's closing on January 2.

Cipla gets USFDA approval for anti-hepatitis B drug; shares gain

Shares of pharma major Cipla rose 1.5 percent intraday Thursday on final approval from the US health regulator for anti-hepatitis B drug.

Biosimilar insulin Glargine to make $100 m from FY18: Biocon

Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

Natco Pharma signs agreement for mfg, sale of hepatitis C drug

Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir to treat patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Aurobindo gets USFDA nod for hepatitis B drug

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Entecavir tablets in strengths of 0.5mg and 1mg, Aurobindo Pharma said in a statement.

Bitter pill for pharma: Govt pushes for compulsory licenses

The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.

Wockhardt jumps on US FDA nod for copy of clot-buster drug

Wockhardt shares hit a 52-week high of Rs 1,275.50 on NSE on Thursday after the drug maker said it has received final US Food and Drugs Administration (FDA) approval to market Clopidogrel bi-sulfate tablets, used to help reduce risk of heart attack or stroke, in in 75 mg strength.

Aurobindo gets US FDA nod to market diabetes control drug

Generics drugs maker Aurobindo Pharma has received final approval from US Food and Drugs Administration (FDA) to manufacture and market Metformin Hydrochloride extended-release tablets in 500mg and 750mg strength.

Bristol-Myers to buy Amylin for about $5.3 bln

Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about USD 5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.

As governor, Romney picked winners and losers of his own

It would be a triumphant moment for any governor: A cutting-edge company announces plans to build a new plant that will create hundreds of high-paying jobs and bolster one of the state's most prominent industries.